Astrocytic Regulation of aberrant perineuronal net formation in Mecp2 -null Neocortex

Area of Science:

• Neuroscience
• Developmental Biology
• Extracellular Matrix Biology

Background:

• Rett syndrome (RTT) is a neurological disorder caused by MECP2 mutations, leading to disrupted brain development and plasticity.
• Perineuronal nets (PNNs), crucial for neuronal plasticity and brain maturation, form precociously in RTT, contributing to early closure of critical developmental periods.
• The mechanisms underlying precocious PNN formation in RTT, particularly the roles of cell-autonomous versus non-cell-autonomous factors, remain largely unknown.

Purpose of the Study:

• To investigate the cellular and molecular mechanisms driving precocious PNN formation in the context of RTT.
• To determine whether astrocytes contribute to the aberrant PNN development observed in RTT.
• To identify potential therapeutic targets for restoring developmental plasticity in RTT.

Main Methods:

• Analysis of astrocyte-conditioned media from Mecp2-null and wildtype astrocytes.
• Assessment of key PNN/extracellular matrix (ECM) component expression (e.g., HAPLN1) in neuronal cultures and developing cortex.
• Histological and biochemical characterization of PNN structure and maturity in Mecp2-null and wildtype models.

Main Results:

• Conditioned media from Mecp2-null astrocytes induced higher expression of HAPLN1 and enhanced PNN formation on wildtype neurons.
• Increased expression of HAPLN1 and other PNN/ECM components was observed in the developing Mecp2-null cortex.
• PNNs in the Mecp2-null cortex exhibited structural and biochemical maturity at an earlier developmental stage compared to wildtype.

Conclusions:

• Mecp2-null astrocytes play a significant role in the precocious formation of PNNs in RTT, suggesting non-cell-autonomous mechanisms are involved.
• Aberrant PNN development in RTT is characterized by early structural and biochemical maturation.
• These findings identify astrocyte-mediated PNN alterations as a potential target for therapeutic intervention in RTT to reverse early critical period closure.